2021
DOI: 10.1016/j.cllc.2021.04.005
|View full text |Cite
|
Sign up to set email alerts
|

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Abstract: Patients with extensive-stage small-cell lung cancer (ED-SCLC) need improved outcomes in the relapsed/refractory setting. This phase II study evaluated the safety and efficacy of prexasertib, a checkpoint kinase 1 inhibitor, in platinum-sensitive and platinum-refractory ED-SCLC. Prexasertib demonstrated response rates of 5.2% in platinum-sensitive and 0% in platinum-refractory ED-SCLC. Prexasertib did not show prespecified efficacy as monotherapy in ED-SCLC. Background: This study assessed the checkpoint kinas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
22
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(23 citation statements)
references
References 25 publications
1
22
0
Order By: Relevance
“…Neutrophil count decreases were also observed in randomized phase III trials of PARP inhibitors, especially with niraparib and talazoparib, but G ≥ 3 events were not frequent and febrile neutropenia was rare [ 25 , 26 ]. Similar results emerged in early phase trials with the WEE1 inhibitor adavosertib [ 40 , 41 , 42 , 52 ], while neutropenia was common and often severe with elimusertib and prexasertib [ 23 , 35 , 37 , 38 , 39 ]. Indeed, the rate of G3/4 events was 54% with the ATR inhibitor and reached 93% with the CHK1 inhibitor.…”
Section: Safety Profile Of Ddr-targeting Agentssupporting
confidence: 61%
See 3 more Smart Citations
“…Neutrophil count decreases were also observed in randomized phase III trials of PARP inhibitors, especially with niraparib and talazoparib, but G ≥ 3 events were not frequent and febrile neutropenia was rare [ 25 , 26 ]. Similar results emerged in early phase trials with the WEE1 inhibitor adavosertib [ 40 , 41 , 42 , 52 ], while neutropenia was common and often severe with elimusertib and prexasertib [ 23 , 35 , 37 , 38 , 39 ]. Indeed, the rate of G3/4 events was 54% with the ATR inhibitor and reached 93% with the CHK1 inhibitor.…”
Section: Safety Profile Of Ddr-targeting Agentssupporting
confidence: 61%
“…Thrombocytopenia was less frequent in phase III randomized trials of other PARP inhibitors, with a G ≥ 3 rate below 10% ( Table 1 ). Decreased platelet counts were also observed in early phase studies of elimusertib [ 35 ], prexasertib [ 23 , 37 , 38 , 39 ] and adavosertib, where it was mainly G1-2 [ 40 , 41 , 42 , 52 ]. In case of thrombocytopenia, treatment should be withheld for values <100,000 with niraparib and <50,000 with olaparib, rucaparib and talazoparib, and then restarted at the same or at a lower dose level after count normalization [ 25 , 26 ].…”
Section: Safety Profile Of Ddr-targeting Agentsmentioning
confidence: 92%
See 2 more Smart Citations
“…In phase 1 trials, treatment with prexasertib caused a high frequency of grade 4 neutropenia, ranging from 50% to 73%, although the effects were transient and reversible (Table 3) [93,94]. Phase 2 studies have been conducted in high-grade serous ovarian cancer [95], triple-negative breast cancer (TNBC) [96], and small cell lung cancer (SCLC) [97]. Although the efficacy was low for SCLC and modest for TNBC, prexasertib showed promising efficacy in ovarian cancer.…”
Section: Chk1/2 Inhibitorsmentioning
confidence: 99%